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Phase II Study of Gemcitabine and Cisplatin in Patients
with Previously Untreated Extensive Stage Small Cell Lung
Cancer: Southwest Oncology Group Study 9718
Paul J. Hesketh, MD,* Kari Chansky, MS,† Valerie Israel, DO,‡ Richard T. Grapski, MD,§
Tarek M. Mekhail, MD, C. Harris Spiridonidis, MD,¶ Glenn M. Mills, MD,# Karen Kelly, MD,**
John J. Crowley, PhD,† and David R. Gandara, MD††
Background: This phase II study (S9718) evaluated the antineo-
plastic activity and tolerability of the combination of gemcitabine
and cisplatin in previously untreated patients with extensive stage
small cell lung cancer (ES-SCLC).
Methods: Chemonaive patients with ES-SCLC, received gemcitab-
ine 1250 mg/m2 intravenously (IV) over 30 minutes on days 1 and
8 and cisplatin 75 mg/m2 IV over 30 to 60 minutes on day 1.
Treatments were repeated every 21 days for a maximum of six
cycles.
Results: A total of 88 patients were enrolled in the study; seven
patients were not eligible and one did not receive treatment; 80
patients were fully assessable for survival, response, and toxicity.
Objective response was observed in 42 patients (53%; 95% confi-
dence interval [CI]: 41%–64%) with two patients (3%; 95% CI:
0%–8%) achieving a complete response. Median PFS was 5 months
(CI, 4.2-5.9 months), and median overall survival was 8.8 months
(95% CI: 7.8–9.5 months). The 1- and 2-year survival rates were
27.5% (95% CI: 17.7%–37.3%) and 4% (95% CI: 0%–8%), respec-
tively. The most common toxicity was neutropenia. Grade 3 and 4
neutropenia was noted in 17 (21%) and 17 (21%) patients, respec-
tively. Two patients developed febrile neutropenia, with subsequent
full recovery. Twenty-one patients (23%) developed grade 3 throm-
bocytopenia. Grade 4 thrombocytopenia was seen in only one
patient. The most common nonhematologic toxicities included grade
3 and 4 vomiting in 12 (21%) patients and fatigue in nine (10%)
patients. Two patients (3%) died of respiratory infections while on
treatment.
Conclusion: The combination of gemcitabine and cisplatin is an
active and reasonably well tolerated regimen for the treatment of
ES-SCLC. It does not appear to offer any compelling advantages
over other commonly used two drug regimens in this disease.
Key Words: Cisplatin, Gemcitabine, Small cell lung cancer, Lung
cancer, Small cell, Chemotherapy.
(J Thorac Oncol. 2007;2: 440–444)
Of the estimated 213,000 new cases of lung cancer thatwill be diagnosed in the United States in 2007, approx-
imately 15% to 20% will have a small cell subtype.1,2 For the
two thirds of patients presenting with extensive stage small
cell lung cancer (ES-SCLC), effective short-term palliation
can be achieved with chemotherapy, but cure is rare. The
current standard of care for patients with ES-SCLC and a
good performance status is four to six cycles of cisplatin or
carboplatin combined with etoposide or irinotecan.3–6 New
treatment approaches incorporating other chemotherapy
agents with activity in SCLC are warranted.
Gemcitabine is an antimetabolite analogue of the nu-
cleoside deoxycytidine with two fluorine atoms incorporated
into the sugar ring.7–9 It is metabolized intracellularly to the
active 5=-di- and 5=-triphosphates, which inhibit DNA poly-
merization. Gemcitabine has demonstrated antineoplastic ac-
tivity against a broad spectrum of solid tumors and is cur-
rently approved for use in pancreatic, breast, ovarian and
non-small cell lung cancers (NSCLC).
Initial interest in gemcitabine in SCLC was stimulated
by its in vitro antitumor activity in two SCLC cell lines, 54A
and 54B.10 This led the National Cancer Institute of Canada
(NCI-C) Clinical Trials Group to conduct a phase II trial of
gemcitabine in previously untreated patients with SCLC.11
Twenty-nine patients with ES-SCLC extensive stage disease
were enrolled in the study. Patients were treated on a weekly
schedule for three consecutive weeks, with treatment cycles
repeated every 28 days. The first 17 patients received gem-
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citabine at a dose of 1000 mg/m2 and the last 12 patients
received a dose of 1250 mg/m2. The overall response rate in
the 26 assessable patients was 27%. The median duration of
response was 12.5 weeks and median survival was 12
months. The regimen was well tolerated with modest hema-
tologic toxicity.
The most active current standard chemotherapy regi-
men in SCLC is a combination of cisplatin with etoposide
(PE). Gemcitabine and cisplatin is an attractive doublet be-
cause of their different mechanisms of action and nonover-
lapping toxicities. Furthermore, this two-drug combination
has demonstrated significant antineoplastic activity with rea-
sonable toxicity in a number of solid tumors such as transi-
tional cell carcinoma of the urothelium and NSCLC.12,13 The
current trial was undertaken by the Southwest Oncology
Group (SWOG) to evaluate the efficacy of gemcitabine plus
cisplatin in chemotherapy-naive patients with ES-SCLC. The
schedule and chemotherapy doses employed in this trial were
derived from a phase III study conducted in NSCLC.14
PATIENTS AND METHODS
Eligibility
Patients were required to have histologically or cyto-
logically confirmed ES-SCLC. Patients were considered to
have extensive disease if their tumor extended beyond one
hemithorax, mediastinal, hilar, or supraclavicular area that
could not be encompassed within a single radiation port. All
patients were required to have measurable or assessable
disease documented by computed tomography, magnetic res-
onance imaging, radiography, physical or nuclear examina-
tion; be 18 years of age or older; have a performance status of
0–2; and have acceptable hepatic, cardiac, hematologic, and
renal function as documented by a serum creatinine less than
or equal to the institutional upper limit of normal and calcu-
lated creatinine clearance of 50 ml/min or more. Previous
radiation therapy and previous surgery for SCLC were al-
lowed, but previous chemotherapy was not. At least 2 weeks
must have elapsed since surgery or completion of radiother-
apy, and patients must have recovered from all associated
toxicities. Patients with brain metastases were eligible if the
brain metastases were treated and/or asymptomatic. No pre-
vious malignancies were allowed other than adequately
treated nonmelanoma skin cancer, in situ cervical cancer,
adequately treated stage I or II cancer from which the patient
was in complete remission, or any other cancer from which
the patient had been disease free for at least 5 years. All
patients were informed of the investigational nature of this
study and signed a written informed consent in accordance
with local institutional review board and federal guidelines.
Treatment Plan
Patients received gemcitabine 1250 mg/m2 intrave-
nously (IV) over 30 minutes on days 1 and 8 and cisplatin 75
mg/m2 IV over 30 to 60 minutes on day 1 of each cycle.
Treatments were repeated every 21 days for a maximum of
six cycles. Patients continued on treatment until disease
progression or completion of six cycles, whichever occurred
first. Appropriate antiemetic regimens containing a 5-hy-
droxytryptamine antagonist were recommended for all pa-
tients. Recommendations for pretreatment hydration before
cisplatin included 1 to 2 liters of 5% dextrose in normal saline
or normal saline over 10 to 24 hours if given as an inpatient
or 1 liter over a minimum of 4 hours as an outpatient.
Prophylactic use of granulocyte colony–stimulating factor
was not permitted. Granulocyte colony–stimulating factor
could be used for the treatment of prolonged neutropenia or
for febrile neutropenia. Treatment at the time of disease
recurrence or progression after six cycles was at the discre-
tion of the individual investigator.
Dose Modifications
Patients experiencing a nadir granulocyte count of less
than 500/l or a nadir platelet count of less than 10,000/l or
requiring the use of granulocyte colony–stimulating factor
were required to undergo a permanent 25% dose reduction of
gemcitabine. If the neutrophil count was less than 1500/l
and/or the platelet count was less than 100,000/l on day 1 of
any cycle, chemotherapy was held until recovery. Day 8
gemcitabine was omitted if the absolute neutrophil count was
less than 1000/l and/or the platelet count was less than
75,000/l. If the absolute neutrophil count was between 1000
and 1499/l or the platelet count was between 75,000 and
99,000/l, on day 8, gemcitabine dose was reduced to 750
mg/m2. All gemcitabine dose reductions were permanent.
Dose modifications for other grade 3 and 4 toxicities were
specified in the protocol. Patients who required longer than a
2-week delay in treatment were removed from the study.
Response and Toxicity Criteria
Standard SWOG criteria were used for response deter-
mination.15 Progression-free survival (PFS) was calculated
from the date of entry into the study to the date of documen-
tation of progression or death (in the absence of progression).
Survival was calculated from the date of entry into the study
until the date of death. Both intervals were determined using
the Kaplan-Meier method. Toxicity grading was done accord-
ing to the Common Toxicity Criteria, version 2.0.16 Complete
blood counts were obtained before each treatment adminis-
tration and serum chemistries obtained at the beginning of
each 21-day cycle. Disease was reassessed at 9 weeks, 18
weeks, and at least every 6 months after treatment was
completed.
Statistical Considerations
The main objective of S9718 was to test whether the
combination of gemcitabine and cisplatin has promise in
terms of increasing survival and response rates in patients
with ES-SCLC. The regimen would be considered promising
if the true median survival from registration was 13.5 months
or longer and would be considered of no further interest if the
true median survival was 9 months or shorter. With a planned
75 patients accrued over 18 months, an additional 1 year of
follow-up and assuming exponential survival, the power of a
one-sided 0.05 level test of 9- versus 13.5-month survival
would be 0.80. Response rates (confirmed plus unconfirmed,
complete, and partial) and rates of specific toxicities could be
estimated to within at worst 11% (95% confidence interval
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[CI]) with 75 patients. Any toxicity occurring with at least
5% probability was likely to be seen with 75 patients at least
once (97.9% chance).
Overall survival and PFS were determined based on the
method of Kaplan and Meier.17 CIs for the median overall
and PFS were calculated according to the method of Brook-
meyer and Crowley.18
RESULTS
Patient Characteristics
Between July of 1998 and June of 1999, 88 patients
were enrolled in the study. Seven patients were ineligible:
two did not have extensive stage disease, one had a histology
other than small cell, and four had inadequate documentation
of eligibility requirements. Another patient refused to receive
any protocol treatment and was not included in this analysis.
The remaining 80 patients were eligible and assessable for
survival, response, and toxicity. Their characteristics are
displayed in Table 1. The median age was 61 (range, 38–78)
and a slight majority of patients (52%) were male. Most
patients had a performance status of 0-1, but 14 patients
(17%) had a performance status of 2.
Response and Survival
Response to treatment is displayed in Table 2. Objec-
tive response was observed in 42 patients (53%; 95% CI:
41%–64%) with two patients (3%; 95% CI: 0%–8.7%)
achieving a complete response. Progressive disease or early
death occurred in 15 (19%) patients. Four (5%) patients had
stable disease. Inadequate assessments precluded response
determination in 19 patients. Median PFS was 5 months (95%
CI: 4.2–5.9 months), and median overall survival was 8.8
months (95% CI: 7.8–9.5 months) (Figure 1). The 1- and
2-year survival rates were 27.5% (95% CI: 17.7%–37.3%)
and 4% (95% CI: 0–8%), respectively.
Toxicity
All 80 eligible patients are assessable for toxicity. The
most frequent grade 3 and 4 toxicities are listed in Table 3.
The most common toxicity was neutropenia. Grade 3 and 4
neutropenia was noted in 17 (21%) and 17 (21%) patients,
respectively. Twenty-six percent (21 patients) developed
grade 3 thrombocytopenia, but grade 4 thrombocytopenia
was seen in only one patient. Three (4%) patients received
platelet transfusions, and seven (9%) patients received
packed red blood cell transfusions. Two patients developed
febrile neutropenia with full recovery. The most significant
nonhematologic toxicities included grade 3 nausea in 18
patients (23%), grades 3 and 4 vomiting in 12 patients (15%),
fatigue in nine patients (11%), constipation/bowel obstructionTABLE 1. Patient Characteristics (n  80)
Variable No. of Patients %
Median age, yr (range) 61.0 (38–78)
Male:female 42:38 52:48
Performance status, 0–1:2 66:14 83:17
Previous radiation therapy
Yes 2 3
No 78 97
Previous surgery
Yes 2 3
No 78 97
FIGURE 1. Overall survival from time of trial registration for
the 80 eligible patients.
TABLE 2. Treatment Outcome (n  80)
Response No. of Patients %
Overall 42 53 (41–64)a
Complete 2 3
Partial 40 50
Stable 4 5
Progressing disease 13 16
Early death 2 3
Assessment inadequate 19 24
a 95% confidence interval.
TABLE 3. Toxicity (Grade 3 or Higher) (n  0)
Grade 3 Grade 4 Grade 5
Adverse Effect
No. (%)
of Pts
No. (%)
of Pts
No. (%)
of Pts
Hematologic/infections
Neutropenia 17 (21) 17 (21) 0 (0)
Leukopenia 13 (16) 5 (1) 0 (0)
Thrombocytopenia 21 (26) 1 (1) 0 (0)
Anemia 9 (11) 1 (1) 0 (0)
Respiratory infection 1 (1) 0 (0) 2 (3)
Gastrointestinal
Nausea 18 (23) 0 (0) 0 (0)
Vomiting 11 (14) 1 (1) 0 (0)
Constipation/bowel
obstruction
7 (9) 0 (0) 0 (0)
Constitutional
Fatigue/malaise/lethargy 9 (11) 0 (0) 0 (0)
Metabolic
Hyponatremia 3 (4) 3 (4) 0 (0)
Maximum grade any
toxicity
37 (46) 23 (29) 2 (3)
pts, patients.
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in seven patients (9%), and hyponatremia in six patients
(8%). No patient developed grade 3 or higher renal insuffi-
ciency, ototoxicity, or peripheral neuropathy. Two patients
(3%) died of treatment-related causes (respiratory infections).
Only 32 patients (40%) completed all six cycles of
treatment. Twenty-patients (25%) discontinued treatment due
to toxicity, and 19 patients (24%) discontinued chemotherapy
due to disease progression. The remaining nine patients
stopped therapy for the following reasons: no response (two
patients), development of symptoms in previously detected
brain metastases (one patient), death due to respiratory infec-
tion (one patient), refusal unrelated to adverse events (one
patient), declining performance status (one patient), nontreat-
ment-related severe syncopal episodes (one patient), incorrect
assessment of disease progression (one patient), and detection
of superior vena cava syndrome that required radiotherapy
(one patient).
DISCUSSION
Since the establishment of PE as the standard of care
for treatment of ES-SCLC in the early 1980s, many attempts
have been made to further improve therapeutic outcome in
this disease. These efforts have included substituting another
agent for etoposide, replacing cisplatin with carboplatin,
using nonplatinum doublets or platinum-based triplets, and
using alternating or sequential regimens or high-dose chemo-
therapy with hematopoietic stem cell support.19 To date, none
of these approaches have been better than PE.
The current study was developed by the SWOG after
the demonstration by the NCI-C in 1994 of the promising
activity and favorable toxicity profile of single-agent gemcit-
abine in previously untreated patients with ES-SCLC.11 Eval-
uating its use in combination with cisplatin appeared to be a
logical next step given the nonoverlapping toxicities and
different mechanisms of action of these two agents and the
promising activity of this combination in a number of other
solid tumors including NSCLC. S9718 represents the first and
only study evaluating the combination of gemcitabine and
cisplatin as initial systemic therapy in patients with ES-
SCLC. We have demonstrated that this regimen is active and
has a relatively favorable toxicity profile. The median sur-
vival of 8.8 months is comparable with the outcome with
many previous phase II studies in ES-SCLC but does not
suggest any substantial advantage for this regimen over the
standard PE.
The activity of gemcitabine in ES-SCLC has been
further validated in trials evaluating its use as second-line
treatment and in combination with carboplatin. The Eastern
Cooperative Oncology Group performed a phase II trial of
gemcitabine 1000 mg/m2 on days 1, 8, and 15 of a 28-day
cycle in 46 patients with SCLC who had experienced treat-
ment failure with one previous chemotherapy regimen.20 An
objective response was noted in 11.9% of patients with an
overall median survival of 7.1 months. A subsequent phase II
trial evaluated the combination of carboplatin (area under the
curve of 5) on day 1 and gemcitabine 1100 mg/m2 on days 1
and 8 of a 21-day cycle in 69 patients with ES-SCLC.21
Overall response rate was 43%, and median survival was 9.2
months.
Efforts have been made to build on the single-agent
activity of gemcitabine by incorporating it into triplet regi-
mens. As has been the case with other such efforts with triplet
regimens, no compelling evidence of improved antineoplastic
efficacy was noted, although toxicity was increased with the
three-drug combination.22 In a randomized phase II study, the
combination of cisplatin, etoposide, and gemcitabine was
compared with cisplatin plus gemcitabine in 140 patients with
ES-SCLC or poor-prognosis limited-stage SCLC.23 Similar
response rates (63% versus 57%), time to disease progression
(6 months versus 7 months), and median survival (9.5 months
versus 10 months) were noted in the cisplatin, etoposide, and
gemcitabine and cisplatin plus gemcitabine arms, respec-
tively. The PEG regimen was associated with more severe
hematologic toxicity.
Recently, SWOG reported the preliminary results of a
phase II trial evaluating the incorporation of gemcitabine into
a nonplatinum doublet in ES-SCLC.24 Eighty-four previously
untreated patients received a combination of gemcitabine
1000 mg/m2 and irinotecan 100 mg/m2 on days 1 and 8 of a
21-day cycle. Response rate was a disappointing 32%, and
median survival was 9 months.
In conclusion, this multicenter phase II trial has dem-
onstrated that the combination of gemcitabine and cisplatin is
an active and reasonably well tolerated regimen for the
treatment of ES-SCLC. However, it clearly does not offer any
compelling advantages compared with other commonly used
two-drug regimens in this disease and will not be further
pursued by SWOG. Ultimately, further progress may await
better insights into the molecular biology of SCLC. Ap-
proaches using molecularly targeted agents have been asso-
ciated with a modest degree of success in non-NSCLC.
Incorporation of mechanism-based biologic agents into the
treatment of SCLC is awaited with interest.
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